Blinatumomab in Pediatric Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: RIALTO Expanded Access Study Final Analysis

The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T cell engager molecule, for treatment of pediatric relapsed/refractory B cell precursor acute lymphoblastic leukemia were examined in an open-label, single-arm, expanded access study (RIALTO).